Why Is Viracta Therapeutics Inventory Buying and selling Decrease At present? – Viracta Therapeutics (NASDAQ:VIRX)

Monday, Viracta Therapeutics Inc VIRX reported topline outcomes from Stage 1 of the pivotal Section 2 NAVAL-1 trial from each arms of the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) cohort. 

Sufferers have been randomized to both nanatinostat monotherapy (n=10) or nanatinostat together with valganciclovir (Nana-val, n=10). 

Nana-val (nanatinostat together with valganciclovir) demonstrated better efficacy than nanatinostat monotherapy and was usually well-tolerated. The median length of response continues to mature.

Efficacy was evaluated as of the February 7, 2024 information cutoff date.

• Within the Nana-val arm, the general response charge (ORR) was 50%, and the whole response charge (CRR) was 20% within the intent-to-treat (ITT) inhabitants (N=10); the ORR was 71%, and the CRR was 29% within the efficacy-evaluable inhabitants (N=7).

Within the nanatinostat monotherapy arm, the ORR and CRR have been 10% and 0%, respectively, within the ITT inhabitants (N=10), and the ORR was 13% within the efficacy-evaluable inhabitants (N=8).

• 5 nanatinostat monotherapy sufferers crossed over to obtain Nana-val, two of whom stay on Nana-val therapy with secure illness as of the info cutoff.

Security was additionally evaluated as of the February 7, 2024 information cutoff date.

The most typical treatment-related opposed occasions in each therapy arms have been thrombocytopenia, anemia, fatigue, decreased urge for food, nausea, diarrhea, and weight reduction.

These opposed occasions have been primarily gentle to average in severity and customarily manageable or reversible.

Worth Motion: VIRX shares are down 15.7% at $0.97 on the final examine Monday.

Illustration of Phrama lab employee created with MidJourney.